(NASDAQ: MIRM) Mirum Pharmaceuticals's forecast annual revenue growth rate of 18.71% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Mirum Pharmaceuticals's revenue in 2025 is $379,251,000.On average, 4 Wall Street analysts forecast MIRM's revenue for 2025 to be $22,292,055,557, with the lowest MIRM revenue forecast at $21,942,241,442, and the highest MIRM revenue forecast at $22,567,022,726. On average, 5 Wall Street analysts forecast MIRM's revenue for 2026 to be $26,441,528,595, with the lowest MIRM revenue forecast at $25,064,562,754, and the highest MIRM revenue forecast at $28,165,435,537.
In 2027, MIRM is forecast to generate $31,581,497,674 in revenue, with the lowest revenue forecast at $29,686,101,569 and the highest revenue forecast at $33,556,793,265.